WVE as reported
Wave Life Sciences Ltd. reported $111M of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed.
$111M
Revenue, trailing twelve months · to Q2 2024 · every figure below is as filed, with no scoring applied
- Net Income
- −$184M
Net Income · +63% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- −$185M
Free Cash Flow · +2.0% year on year · trailing twelve months to Q1 2026
- EPS
- −$1.05
EPS · +42% year on year · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $111M | n/a | Q2 2024 · 7 quarters behind |
| Net Income | −$184M | +63% | Q1 2026 |
| EPS | −$1.05 | +42% | Q1 2026 |
| Op Margin | −127% | n/a | Q2 2024 · 7 quarters behind |
| Net Margin | −115% | n/a | Q2 2024 · 7 quarters behind |
| ROE | −67% | n/a | Q1 2026 |
| ROA | −41% | n/a | Q1 2026 |
| Free Cash Flow | −$185M | +2.0% | Q1 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Wave Life Sciences Ltd. (WVE) - Revenue & ProfitRevenue & ProfitWave Life Sciences Ltd. (WVE)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com